Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ependymoma × brigatinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 19 Lung Neoplasms 8 Lymphoma, Large-Cell, Anaplastic 4 Carcinoma 4 Carcinoma, Squamous Cell 2 Carcinoma, Large Cell 2 Brain Neoplasms 2 Adenocarcinoma 2 ALK-positive Advanced NSCLC 2 Sexual Dysfunction, Physiological 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Neoplasms 1 Neoplasm Metastasis 1 NSCLC 1 Meningioma 1 Granuloma, Plasma Cell 1 Gastrointestinal Neoplasms 1 Eunuchism 1 Erectile Dysfunction 1 Ependymoma 1 Disease Progression 1 Carcinoma, Pancreatic Ductal 1 Breast Neoplasms 1 ALK-positive NSCLC 1 ALK+ Advanced NSCLC 1

Interventions

Temozolomide 24 Magnetic Resonance Spectroscopy 16 Etoposide 13 Cyclophosphamide 12 Filgrastim 10 Bevacizumab 9 Radiotherapy 8 Carboplatin 8 Biopsy 8 X-Rays 6 Specimen Handling 6 Phantoms, Imaging 6 Cisplatin 6 Thiotepa 5 Nuclear Medicine Department, Hospital 5 Nivolumab 5 Irinotecan 5 Carmustine 5 sargramostim 4 Vincristine 4 Radiation 4 Peripheral Blood Stem Cell Transplantation 4 Methotrexate 4 Erlotinib Hydrochloride 4 etoposide phosphate 3 Surveys and Questionnaires 3 Lapatinib 3 Granulocyte Colony-Stimulating Factor 3 Gadolinium DTPA 3 Azacitidine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04374305 2026-01-12

INTUITT-NF2

Massachusetts General Hospital

Phase 2 Active not recruiting

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡